SHOCKWAVE MEDICAL INC (SWAV) Fundamental Analysis & Valuation
NASDAQ:SWAV • US82489T1043
Current stock price
334.75 USD
-0.08 (-0.02%)
At close:
334.8 USD
+0.05 (+0.01%)
After Hours:
This SWAV fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. SWAV Profitability Analysis
1.1 Basic Checks
- In the past year SWAV was profitable.
- SWAV had a positive operating cash flow in the past year.
- In multiple years SWAV reported negative net income over the last 5 years.
- The reported operating cash flow has been mixed in the past 5 years: SWAV reported negative operating cash flow in multiple years.
1.2 Ratios
- SWAV has a better Return On Assets (9.95%) than 93.23% of its industry peers.
- The Return On Equity of SWAV (21.76%) is better than 95.31% of its industry peers.
- SWAV has a better Return On Invested Capital (8.81%) than 88.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.95% | ||
| ROE | 21.76% | ||
| ROIC | 8.81% |
ROA(3y)13.4%
ROA(5y)-1.2%
ROE(3y)20.17%
ROE(5y)0.98%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- SWAV has a Profit Margin of 20.76%. This is amongst the best in the industry. SWAV outperforms 94.79% of its industry peers.
- Looking at the Operating Margin, with a value of 20.52%, SWAV belongs to the top of the industry, outperforming 94.27% of the companies in the same industry.
- SWAV has a Gross Margin of 86.99%. This is amongst the best in the industry. SWAV outperforms 96.35% of its industry peers.
- SWAV's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.52% | ||
| PM (TTM) | 20.76% | ||
| GM | 86.99% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.99%
GM growth 5Y16.42%
2. SWAV Health Analysis
2.1 Basic Checks
- SWAV has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- The number of shares outstanding for SWAV has been increased compared to 1 year ago.
- Compared to 1 year ago, SWAV has a worse debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 10.26 indicates that SWAV is not in any danger for bankruptcy at the moment.
- SWAV has a Altman-Z score of 10.26. This is amongst the best in the industry. SWAV outperforms 86.98% of its industry peers.
- SWAV has a debt to FCF ratio of 4.41. This is a neutral value as SWAV would need 4.41 years to pay back of all of its debts.
- With an excellent Debt to FCF ratio value of 4.41, SWAV belongs to the best of the industry, outperforming 82.81% of the companies in the same industry.
- A Debt/Equity ratio of 0.97 indicates that SWAV is somewhat dependend on debt financing.
- The Debt to Equity ratio of SWAV (0.97) is worse than 76.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.97 | ||
| Debt/FCF | 4.41 | ||
| Altman-Z | 10.26 |
ROIC/WACC0.94
WACC9.36%
2.3 Liquidity
- SWAV has a Current Ratio of 13.81. This indicates that SWAV is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of SWAV (13.81) is better than 97.92% of its industry peers.
- A Quick Ratio of 12.61 indicates that SWAV has no problem at all paying its short term obligations.
- SWAV has a Quick ratio of 12.61. This is amongst the best in the industry. SWAV outperforms 97.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.81 | ||
| Quick Ratio | 12.61 |
3. SWAV Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an nice 12.34% over the past year.
- The Revenue has grown by 41.44% in the past year. This is a very strong growth!
- The Revenue has been growing by 126.31% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)12.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.81%
Revenue 1Y (TTM)41.44%
Revenue growth 3Y120.84%
Revenue growth 5Y126.31%
Sales Q2Q%35.85%
3.2 Future
- The Earnings Per Share is expected to grow by 17.56% on average over the next years. This is quite good.
- The Revenue is expected to grow by 20.10% on average over the next years. This is a very strong growth
EPS Next Y36.11%
EPS Next 2Y27.65%
EPS Next 3Y24.15%
EPS Next 5Y17.56%
Revenue Next Year27.69%
Revenue Next 2Y24.82%
Revenue Next 3Y23.61%
Revenue Next 5Y20.1%
3.3 Evolution
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. SWAV Valuation Analysis
4.1 Price/Earnings Ratio
- SWAV is valuated quite expensively with a Price/Earnings ratio of 78.21.
- 67.19% of the companies in the same industry are more expensive than SWAV, based on the Price/Earnings ratio.
- SWAV is valuated expensively when we compare the Price/Earnings ratio to 26.11, which is the current average of the S&P500 Index.
- Based on the Price/Forward Earnings ratio of 53.09, the valuation of SWAV can be described as expensive.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of SWAV indicates a somewhat cheap valuation: SWAV is cheaper than 68.75% of the companies listed in the same industry.
- SWAV is valuated expensively when we compare the Price/Forward Earnings ratio to 24.12, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 78.21 | ||
| Fwd PE | 53.09 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of SWAV indicates a somewhat cheap valuation: SWAV is cheaper than 67.19% of the companies listed in the same industry.
- Based on the Price/Free Cash Flow ratio, SWAV is valued a bit cheaper than the industry average as 75.00% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 75.65 | ||
| EV/EBITDA | 66.43 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- The decent profitability rating of SWAV may justify a higher PE ratio.
- SWAV's earnings are expected to grow with 24.15% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.17
PEG (5Y)N/A
EPS Next 2Y27.65%
EPS Next 3Y24.15%
5. SWAV Dividend Analysis
5.1 Amount
- No dividends for SWAV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SWAV Fundamentals: All Metrics, Ratios and Statistics
334.75
-0.08 (-0.02%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-06 2024-05-06/amc
Earnings (Next)08-05 2024-08-05/amc
Inst Owners10.85%
Inst Owner Change0%
Ins Owners5.23%
Ins Owner Change0%
Market Cap12.57B
Revenue(TTM)787.98M
Net Income(TTM)163.55M
Analysts53.75
Price Target330.75 (-1.19%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.32%
Min EPS beat(2)27.98%
Max EPS beat(2)44.66%
EPS beat(4)3
Avg EPS beat(4)18.35%
Min EPS beat(4)-12.88%
Max EPS beat(4)44.66%
EPS beat(8)7
Avg EPS beat(8)24.97%
EPS beat(12)11
Avg EPS beat(12)73.56%
EPS beat(16)13
Avg EPS beat(16)54.46%
Revenue beat(2)1
Avg Revenue beat(2)1.53%
Min Revenue beat(2)-0.23%
Max Revenue beat(2)3.29%
Revenue beat(4)2
Avg Revenue beat(4)0.86%
Min Revenue beat(4)-1.27%
Max Revenue beat(4)3.29%
Revenue beat(8)5
Avg Revenue beat(8)2.94%
Revenue beat(12)9
Avg Revenue beat(12)5.4%
Revenue beat(16)13
Avg Revenue beat(16)8.23%
PT rev (1m)2.57%
PT rev (3m)25.91%
EPS NQ rev (1m)-2.66%
EPS NQ rev (3m)-2.74%
EPS NY rev (1m)6.44%
EPS NY rev (3m)16.18%
Revenue NQ rev (1m)0.35%
Revenue NQ rev (3m)0.36%
Revenue NY rev (1m)0.78%
Revenue NY rev (3m)0.99%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 78.21 | ||
| Fwd PE | 53.09 | ||
| P/S | 15.95 | ||
| P/FCF | 75.65 | ||
| P/OCF | 63.5 | ||
| P/B | 16.72 | ||
| P/tB | 20.26 | ||
| EV/EBITDA | 66.43 |
EPS(TTM)4.28
EY1.28%
EPS(NY)6.31
Fwd EY1.88%
FCF(TTM)4.42
FCFY1.32%
OCF(TTM)5.27
OCFY1.57%
SpS20.99
BVpS20.03
TBVpS16.52
PEG (NY)2.17
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.95% | ||
| ROE | 21.76% | ||
| ROCE | 10.42% | ||
| ROIC | 8.81% | ||
| ROICexc | 26.17% | ||
| ROICexgc | 34.98% | ||
| OM | 20.52% | ||
| PM (TTM) | 20.76% | ||
| GM | 86.99% | ||
| FCFM | 21.08% |
ROA(3y)13.4%
ROA(5y)-1.2%
ROE(3y)20.17%
ROE(5y)0.98%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.99%
GM growth 5Y16.42%
F-Score5
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.97 | ||
| Debt/FCF | 4.41 | ||
| Debt/EBITDA | 4.22 | ||
| Cap/Depr | 270.11% | ||
| Cap/Sales | 4.03% | ||
| Interest Coverage | 30.21 | ||
| Cash Conversion | 114.09% | ||
| Profit Quality | 101.56% | ||
| Current Ratio | 13.81 | ||
| Quick Ratio | 12.61 | ||
| Altman-Z | 10.26 |
F-Score5
WACC9.36%
ROIC/WACC0.94
Cap/Depr(3y)384.02%
Cap/Depr(5y)409.93%
Cap/Sales(3y)4.85%
Cap/Sales(5y)8.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.81%
EPS Next Y36.11%
EPS Next 2Y27.65%
EPS Next 3Y24.15%
EPS Next 5Y17.56%
Revenue 1Y (TTM)41.44%
Revenue growth 3Y120.84%
Revenue growth 5Y126.31%
Sales Q2Q%35.85%
Revenue Next Year27.69%
Revenue Next 2Y24.82%
Revenue Next 3Y23.61%
Revenue Next 5Y20.1%
EBIT growth 1Y8.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year63.79%
EBIT Next 3Y41.48%
EBIT Next 5Y38.45%
FCF growth 1Y635%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y478.63%
OCF growth 3YN/A
OCF growth 5YN/A
SHOCKWAVE MEDICAL INC / SWAV Fundamental Analysis FAQ
What is the fundamental rating for SWAV stock?
ChartMill assigns a fundamental rating of 6 / 10 to SWAV.
What is the valuation status for SWAV stock?
ChartMill assigns a valuation rating of 4 / 10 to SHOCKWAVE MEDICAL INC (SWAV). This can be considered as Fairly Valued.
What is the profitability of SWAV stock?
SHOCKWAVE MEDICAL INC (SWAV) has a profitability rating of 6 / 10.
Can you provide the expected EPS growth for SWAV stock?
The Earnings per Share (EPS) of SHOCKWAVE MEDICAL INC (SWAV) is expected to grow by 36.11% in the next year.